Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

63.69USD
24 Mar 2017
Change (% chg)

$0.47 (+0.74%)
Prev Close
$63.22
Open
$63.45
Day's High
$64.76
Day's Low
$63.12
Volume
128,090
Avg. Vol
445,135
52-wk High
$75.13
52-wk Low
$32.40

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 2.32
Market Cap(Mil.): $9,075.42
Shares Outstanding(Mil.): 142.49
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.99 -- --
ROI: -19.32 -2.56 13.01
ROE: -21.23 5.14 14.16

Seattle Genetics to resume trials as FDA lifts clinical hold

Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.

Mar 06 2017

UPDATE 1-Seattle Genetics to resume trials as FDA lifts clinical hold

March 6 Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.

Mar 06 2017

FDA lifts hold on Seattle Genetics drug trials

March 6 Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration had lifted the clinical hold on several early stage studies testing its experimental cancer drug.

Mar 06 2017

BRIEF-FDA lifts hold on Seattle Genetics' phase 1 trials of vadastuximab talirine

* FDA lifts clinical hold on seattle genetics' phase 1 trials of vadastuximab talirine

Mar 06 2017

Immunomedics in $2 bln licensing deal with Seattle Genetics

Drug developer Immunomedics Inc said on Friday it entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.

Feb 10 2017

UPDATE 3-Immunomedics in $2 bln licensing deal with Seattle Genetics

* Seattle Genetics' stock down 4 pct (Adds details from conf call, recasts; updates shares)

Feb 10 2017

BRIEF-Immunomedics announces postponement of 2016 annual meeting

* Annual meeting has been postponed to march 3, 2017 at 10:00 a.m. Eastern time

Feb 10 2017

BRIEF-Immunomedics enters licensing agreement with Seattle Genetics

* Immunomedics enters into exclusive global licensing agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with potential payments of up to approximately $2 billion, plus royalties

Feb 10 2017

BRIEF-Seattle Genetics in licensing deal with Immunomedics

* Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors

Feb 10 2017

Immunomedics in $2 bln licensing deal with Seattle Genetics

Feb 10 Immunomedics Inc said it entered into a licensing deal for its cancer treatment with Seattle Genetics Inc for a potential payment of up to about $2 billion.

Feb 10 2017

More From Around the Web

Competitors

Earnings vs. Estimates